myeloproliferative disorders

Anagrelide (Xagrid) is a Platelet-reducing Agent. The mechanism of action of anagrelide is as a Phosphodiesterase 3 Inhibitor. The physiologic effect of anagrelide is by means of Decreased Platelet Production.

JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) intended for the treatment of organ transplantation rejection, graft-versus-host reaction post-transplantation, autoimmune disorders, allergic diseases, and chronic myeloproliferative disorders.

BTK-IN-24 is a Bruton's tyrosine kinase (BTK) inhibitor with potential anticancer activity, and it can be used in the study of myeloproliferative disorders.

JAK2-IN-18 (Compound example1) is a selective JAK2 inhibitor. It effectively inhibits the JAK-STAT signaling pathway, with an IC50 value of less than 100 nM for pSTAT5 in HEL9217 cells. JAK2-IN-18 suppresses the proliferation of abnormally proliferating myeloid cells and is useful in research on myeloproliferative disorders, such as essential thrombocythemia.